Key Points. Combining CAR-T cells targeting CD19 & CD22 with a recombinant, polymer-conjugated IL15 receptor agonist (NKTR-255) was safe and feasible.2
The EMA’s CHMP has recommended the approval of imetelstat for transfusion-dependent anemia in lower-risk myelodysplastic syndrome.
During a Case-Based Roundtable® event, Chul Kim, MD, discussed the ALTA-1 trial and BRIGHTSTAR trials of brigatinib in ALK+ lung cancer in the first article…
Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
Annals of Surgical Oncology – While solid pseudopapillary tumor (SPT) of the pancreas are oncologically low-risk tumors, their resection with pancreaticoduodenectomy (PD) or partial pancreatectomy…
Lee et al. show that neutrophil extracellular traps (NETs) establish the pre-metastatic niche in the omentum by recruiting innate-like B cells and eliciting IL-10 production in…
Explore the 2024 CPT codes for oncology patient navigation and how pharma can support improved patient outcomes.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
Fauxcoll gradient, Blood, Volume 115, Issue 13, 1 April 2010, Pages 2567, https://doi.org/10.1182/blood-2010-03-272575
